Algert Global LLC Decreases Stock Position in Alphatec Holdings, Inc. $ATEC

Key Points

• Algert Global LLC has reduced its stake in Alphatec Holdings, Inc. by 11.6%, now holding 145,669 shares valued at approximately $1.48 million.
• Alphatec announced a profit of $0.02 earnings per share for the quarter, surpassing estimates and marking a 27.5% increase in revenue year-over-year.
• Several analysts have upgraded Alphatec's stock rating to "buy", with a consensus price target set at $18.50.

Algert Global LLC cut its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 11.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,669 shares of the medical technology company's stock after selling 19,170 shares during the period. Algert Global LLC owned about 0.10% of Alphatec worth $1,477,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ATEC. GAMMA Investing LLC increased its holdings in Alphatec by 38,433.3% during the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after acquiring an additional 2,306 shares in the last quarter. Comerica Bank grew its position in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Larson Financial Group LLC purchased a new position in shares of Alphatec during the 1st quarter worth approximately $54,000. Quarry LP increased its stake in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Alphatec during the 4th quarter worth approximately $76,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Trading Down 1.4%

Shares of ATEC traded down $0.23 during trading hours on Thursday, hitting $15.96. The stock had a trading volume of 347,093 shares, compared to its average volume of 2,053,790. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $16.47. The firm has a market cap of $2.36 billion, a P/E ratio of -14.12 and a beta of 1.05. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The company's fifty day simple moving average is $12.68 and its 200 day simple moving average is $11.66.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue was up 27.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, COO Scott Lish sold 36,081 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $12.53, for a total transaction of $452,094.93. Following the completion of the sale, the chief operating officer directly owned 708,855 shares in the company, valued at $8,881,953.15. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the completion of the transaction, the executive vice president directly owned 1,463,896 shares in the company, valued at approximately $18,064,476.64. This represents a 11.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 410,247 shares of company stock valued at $5,376,804 over the last ninety days. Corporate insiders own 20.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ATEC shares. Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 target price on shares of Alphatec in a report on Friday, August 1st. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research report on Monday, June 16th. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Finally, Barclays restated an "overweight" rating and issued a $22.00 target price (up from $21.00) on shares of Alphatec in a report on Monday, August 4th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.